Botulinum toxin A in blepharospasm and hemifacial spasm.
We report the first Indian experience of botulinum toxin A in the treatment of blepharospasm and hemifacial spasm. Sixteen patients, 7 with essential blepharospasm, 5 with Meige syndrome and 4 with hemifacial spasm received botulinum toxin A injection. One patient received 3 courses of injections, 2 received 2 courses and the rest received only one course. The effect was observed after a latent period of less than 48 hours in all patients and lasted for a mean of 16.65 weeks. More than 70% improvement occurred after 17/20 injections (85%). Poor response was more often seen when blepharospasm was associated with oromandibular dystonia (2/5 injections). Though the duration of response and subjective score of improvement was best in patients with hemifacial spasm, the numbers were very small for any statistical evaluation. The side effects were local, transient, mild and well tolerated. The commonest side effect was blepharoptosis.
Behari
M
M
Department of Neurology, All India Institute of Medical Sciences, New Delhi.
Singh
K K
KK
Seshadri
S
S
Prasad
K
K
Ahuja
G K
GK
D000328:Adult; D001763:Blepharoptosis / Q000139:chemically induced; D001764:Blepharospasm / Q000188:drug therapy*; D001905:Botulinum Toxins / Q000008:administration & dosage* / Q000009:adverse effects; D005152:Facial Muscles; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D015552:Injections, Intralesional; D008297:Male; D008875:Middle Aged; D013035:Spasm / Q000188:drug therapy*
D001905:Botulinum Toxins